Lymphoma
Conditions
Keywords
stage I adult Burkitt lymphoma, stage III adult Burkitt lymphoma, stage IV adult Burkitt lymphoma, contiguous stage II adult Burkitt lymphoma, noncontiguous stage II adult Burkitt lymphoma, AIDS-related peripheral/systemic lymphoma
Brief summary
RATIONALE: Drugs used in chemotherapy, such as doxorubicin hydrochloride liposome, work in different ways to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing. Monoclonal antibodies, such as rituximab, can block cancer growth in different ways. Some block the ability of cancer cells to grow and spread. Others find cancer cells and help kill them or carry cancer-killing substances to them. Giving rituximab together with combination chemotherapy may kill more cancer cells. PURPOSE: This phase II trial is studying how well giving doxorubicin hydrochloride liposome and rituximab together with combination chemotherapy works in treating patients with newly diagnosed Burkitt's lymphoma or Burkitt-like lymphoma.
Detailed description
OBJECTIVES: Primary * Determine the overall response rate (complete remission, complete remission undetermined, and partial remission) in HIV-negative or HIV-positive patients with newly diagnosed Burkitt's or Burkitt-like lymphoma treated with doxorubicin hydrochloride liposome and rituximab as part of the Magrath regimen. Secondary * Determine the complete remission rate in patients treated with this regimen. * Determine progression-free and overall survival at 2 years in patients treated with this regimen. * Determine the safety of adding rituximab to the standard Magrath regimen in these patients. * Determine the safety of using doxorubicin hydrochloride liposome in place of doxorubicin hydrochloride in these patients. * Determine correlative levels of rituximab and doxorubicin hydrochloride liposome in cerebrospinal fluid and peripheral blood. OUTLINE: This is a multicenter study. Patients are stratified according to risk category (low risk vs high risk). Patients are assigned to 1 of 2 treatment regimens according to stratum. * Regimen A (low-risk disease with no CNS involvement): Patients receive R-CODOX-M chemotherapy comprising rituximab IV over 2-4 hours on days 0 and 8; doxorubicin hydrochloride liposome IV over 30 minutes on day 1; vincristine IV on days 1 and 8; cyclophosphamide IV over 1 hour on days 1-5; and high-dose methotrexate (MTX) IV over 24 hours on day 10. Patients also receive leucovorin calcium IV beginning 36 hours after the start of MTX infusion and continuing every 6 hours until blood levels of MTX are safe. Patients also receive filgrastim (G-CSF) subcutaneously (SC) once daily on days 4-8 in courses 1 and 3 and on days 6 and 7 in course 2. Beginning on day 12, daily G-CSF dosing resumes until blood counts recover. Patients receive CNS prophylaxis comprising cytarabine intrathecally (IT) on day 1 and MTX IT on day 3. Treatment repeats every 28 days for 3 courses in the absence of disease progression or unacceptable toxicity. * Regimen B (high-risk disease with or without CNS involvement): Patients receive R-CODOX-M chemotherapy with leucovorin calcium and G-CSF support as in regimen A for courses 1 and 3 and R-IVAC chemotherapy with leucovorin calcium and G-CSF support (as below) for courses 2 and 4. R-IVAC chemotherapy comprises high-dose ifosfamide IV over 3 hours and etoposide IV over 1 hour on days 1-5; cytarabine IV over 3 hours twice daily on days 2 and 3; and rituximab IV over 2-4 hours on day 0 and on day 6 or 7. Patients also receive leucovorin calcium orally every 6 hours on day 6 and G-CSF SC once daily beginning on day 6 or 7 and continuing until blood counts recover. Patients without CNS involvement receive CNS prophylaxis comprising cytarabine IT on days 1 and 3 and MTX IT on day 15 in courses 1 and 3 and MTX IT alone on day 5 in courses 2 and 4. Patients with proven CNS involvement at diagnosis receive cytarabine IT on days 1, 3, and 5 in course 1, on days 7 and 9 in course 2, and on days 1 and 3 in course 3. These patients also receive MTX IT on days 15 and 17 in course 1, on day 5 in courses 2 and 4, and on day 15 in course 3. Treatment repeats every 28 days for 4 courses in the absence of disease progression or unacceptable toxicity. The first 10 patients enrolled on the study undergo cerebrospinal fluid and blood collection during courses 1 and 3 for correlative biological marker and pharmacological studies. After completion of study treatment, patients are followed at 30 days and then periodically for up to 3 years. PROJECTED ACCRUAL: A total of 25 patients will be accrued for this study.
Interventions
DRUGRegimen A
Cyclophosphamide (800 mg/m2 IV over 1 hour)+ vincristine (1.5 mg/m2 IV PUSH)+ doxorubicin (40 mg/m2 IV)+ high-dose methotrexate (2,700 mg/m2 IV over 23 hours)+ rituximab (500 mg/m2 IV)(R-CODOX-M) regimen
DRUGRegimen B
Rituximab (500 mg/m2 IV once)+ Ifosfamide (1500 mg/m2 IV daily over 3 hours)+ Etoposide (60 mg/m2 IV daily over 1 hour), and Cytarabine (2 grams/m2 IV over 3 hours for 4 doses)
Sponsors
National Cancer Institute (NCI)
Northwestern University
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
DISEASE CHARACTERISTICS: * Histologically confirmed Burkitt's or Burkitt-like non-Hodgkin's lymphoma meeting 1 of the following risk criteria: * Low-risk disease meeting all of the following criteria: * Normal lactate dehydrogenase level * ECOG performance status 0-1 * Ann Arbor stage I or II * No tumor mass over 10 cm in greatest diameter * High-risk disease, defined as disease not meeting low-risk criteria * Newly diagnosed disease PATIENT CHARACTERISTICS: * ECOG performance status 0-2 * Not pregnant or nursing * Negative pregnancy test * Fertile patients must use effective contraception * Hemoglobin ≥ 8.0 g/dL * Absolute neutrophil count ≥ 500/mm³ * Platelet count ≥ 100,000/mm³ (50,000/mm³ if bone marrow involvement is documented) * AST and ALT ≤ 3 times upper limit of normal (ULN) * Alkaline phosphatase ≤ 3 times ULN * Bilirubin ≤ 1.5 times ULN (3 times ULN if liver metastases are present) * Creatinine clearance \> 50 mL/min * Creatinine ≤ 2.0 mg/dL * LVEF ≥ 45% by MUGA scan or echocardiogram * No New York Heart Association class II-IV heart failure * No clinically significant pericardial disease * No myocardial infarction within the past 6 months * No uncontrolled angina * No severe uncontrolled ventricular arrhythmias * No ECG evidence of acute ischemia or active conduction system abnormalities * Investigator must document any baseline ECG abnormality as not medically relevant * No other malignancy within the past year except for basal cell carcinoma of the skin or in situ carcinoma of the cervix * No other serious medical or psychiatric illness that would preclude study compliance PRIOR CONCURRENT THERAPY: * Prior treatment with 1 course of any combination of rituximab, cyclophosphamide, doxorubicin hydrochloride, vincristine, and/or prednisone\* (CHOP)-like therapy allowed, provided the following doses are not exceeded: * Rituximab 750 mg/m² * Cyclophosphamide 1,000 mg/m² * Doxorubicin hydrochloride 50 mg/m² * Vincristine 2 mg/m² * No other investigational drugs within the past 14 days * No other concurrent systemic, cytotoxic, investigational, or chemotherapy agents NOTE: \*No maximum dose restriction on steroids
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Overall Response Rate (ORR) of Patients With Burkitt's and Burkitt-like Lymphoma/Leukemia Treated With Modified Magrath Regimen | After two cycles of treatment and at completion of treatment (4 cycles for high risk and 3 cycles for low risk) up to approximately 20 weeks. | Response Rate is defined as combined number of patients with Complete Remission (CR) Complete Remission undetermined (Cru) and Partial Remission (PR) for patients with Burkitt's and Burkitt-like Lymphoma/Leukemia. Response will be measured by CT scans following treatment completion and assessed using Response Criteria for Non-Hodgkin's Lymphoma where: CR=complete disappearance of all detectable clinical and radiographic evidence of disease and disappearance of all disease-related symptoms. CRu=same as above but allowing for 75% decrease in lymph node masses and indeterminate or normal bone marrow. PR=50% decrease in SPD of the six largest dominant nodes or nodal masses with no increase in size or other nodes, liver, spleen and no new sites of disease. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Overall Survival (OS) of Patients With Burkitt's and Burkitt-like Lymphoma/Leukemia Treated With Modified Magrath Regimen | At 2 years from treatment initiation Median follow up 34 months (range 15-45) | Overall Survival (OS) of patients with Burkitt's and Burkitt-like Lymphoma/Leukemia treated with modified Magrath regimen. OS is defined from the first dose of study drug to the time of death for any reason. |
| Safety of Patients With Burkitt's and Burkitt-like Lymphoma/Leukemia Treated With Modified Magrath Regimen (Addition of Rituximab, Subsitution of Adriamycin for Doxil and Using Lower Dose of Methotrexate) | After each cycle or monthly (whichever is less frequent), 30 days post last dose. Treatment duration was at a median of 13 weeks (range 11-20) for high-risk patients and 10 weeks (range 9-12) for low-risk patients. | Adverse events (AE) graded as either 3 or 4 and determined to be at least possibly related to study treatment will be collected in patients Burkitt's and Burkitt-like Lymphoma/Leukemia treated with modified Magrath regimen to assess the safety and toxicity profile of the addition of rituximab, subsitution of adriamycin for doxil and lower dose of methotrexate. AEs will be assessed as follows at the following time points: At the end of each cycle or monthly whichever is less frequent and 30 days post last dose of study treatment for a maximum of 3 cycles for regimen A and 4 cycles for regimen B and up to 12 months. In general AEs will be assessed according to the National Cancer Institute's Common Toxicity Criteria for adverse events version 3.0 (CTCAE v 3.0). In general adverse events (AEs) will be graded according to the following: Grade 1 Mild AE Grade 2 Moderate AE Grade 3 Severe AE Grade 4 Life-threatening or disabling AE Grade 5 Death related to AE |
| Progression Free Survival (PFS) of Patients With Burkitt's and Burkitt-like Lymphoma/Leukemia Treated With Modified Magrath Regimen | At 2 years from treatment initiation. Median follow up 34 months (range 15-45) | Progression Free Survival (PFS) will be defined from the first dose of study drug to the first documentation of progressive disease or death for any reason. Patients that are lost to follow-up before progression will be censored at the point of last documentation of not experiencing the event. |
Countries
United States
Participant flow
Recruitment details
The study opened for accrual on October 4, 2006 with the first patient enrolling and starting treatment on February 6, 2007 and an accrual goal of up to 25 patients. The study was closed permanently on April 26, 2011 to further accrual with 25 patients enrolled on the study.
Pre-assignment details
Patients were stratified as either high-risk or low-risk. Low Risk= patients with normal Lactic acid dehydrogenase (LDH) level, Eastern Cooperative Oncology Group Performance Status (ECOG PS) of 0 or 1, Ann Arbor stage as I or II and no tumor mass over 10 cm in greatest diameter. High Risk = All other patients
Participants by arm
| Arm | Count |
|---|---|
| High Risk - Treated With Alternating R-CODOX-M/R-IVAC Cycles Patients are stratified between high risk and low risk disease status.
High risk patients receive 1 cycle of R-CODOX-M chemotherapy IV followed by R-IVAC chemotherapy over 30 minutes(Regimen B); regimens A and B are then repeated.
Regimen A: Cyclophosphamide (800 mg/m2 IV over 1 hour)+ vincristine (1.5 mg/m2 IV PUSH)+ doxorubicin (40 mg/m2 IV)+ high-dose methotrexate (2,700 mg/m2 IV over 23 hours)+ rituximab (500 mg/m2 IV)(R-CODOX-M) regimen | 20 |
| Low Risk - Treatment With 3 Cycles of R-CODOX-M Patients are stratified between high risk and low risk disease status. Low risk patients receive 3 cycles of rituximab (500 mg/m2) R-CODOX-M chemotherapy IV over 2-4 hours with intrathecal chemotherapy (Regimen A).
Regimen A: Cyclophosphamide (800 mg/m2 IV over 1 hour)+ vincristine (1.5 mg/m2 IV PUSH)+ doxorubicin (40 mg/m2 IV)+ high-dose methotrexate (2,700 mg/m2 IV over 23 hours)+ rituximab (500 mg/m2 IV)(R-CODOX-M) regimen
Regimen B: Rituximab (500 mg/m2 IV once)+ Ifosfamide (1500 mg/m2 IV daily over 3 hours)+ Etoposide (60 mg/m2 IV daily over 1 hour), and Cytarabine (2 grams/m2 IV over 3 hours for 4 doses) 4 doses) | 5 |
| Total | 25 |
Withdrawals & dropouts
| Period | Reason | FG000 | FG001 |
|---|---|---|---|
| Follow up for 2 Years | Death | 4 | 0 |
| Treatment on Study | Adverse Event | 3 | 1 |
Baseline characteristics
| Characteristic | High Risk - Treated With Alternating R-CODOX-M/R-IVAC Cycles | Low Risk - Treatment With 3 Cycles of R-CODOX-M | Total |
|---|---|---|---|
| Age, Categorical <=18 years | 0 Participants | 0 Participants | 0 Participants |
| Age, Categorical >=65 years | 3 Participants | 1 Participants | 4 Participants |
| Age, Categorical Between 18 and 65 years | 17 Participants | 4 Participants | 21 Participants |
| Ann Arbor Stage Stage I | 1 Participants | 3 Participants | 4 Participants |
| Ann Arbor Stage Stage II | 1 Participants | 2 Participants | 3 Participants |
| Ann Arbor Stage Stage III | 3 Participants | 0 Participants | 3 Participants |
| Ann Arbor Stage Stage IV | 15 Participants | 0 Participants | 15 Participants |
| Bulky disease No | 12 Participants | 5 Participants | 17 Participants |
| Bulky disease Yes | 8 Participants | 0 Participants | 8 Participants |
| Eastern Cooperative Oncology Group Performance Status (ECOG PS) 0 | 8 Participants | 1 Participants | 9 Participants |
| Eastern Cooperative Oncology Group Performance Status (ECOG PS) 1 | 6 Participants | 4 Participants | 10 Participants |
| Eastern Cooperative Oncology Group Performance Status (ECOG PS) 2 | 6 Participants | 0 Participants | 6 Participants |
| Human Immunodeficiency Virus (HIV) Status Negative | 17 Participants | 4 Participants | 21 Participants |
| Human Immunodeficiency Virus (HIV) Status Positive | 3 Participants | 1 Participants | 4 Participants |
| Lactate dehydrogenase (LDH) Level Elevated | 15 Participants | 2 Participants | 17 Participants |
| Lactate dehydrogenase (LDH) Level Within Normal Range | 5 Participants | 3 Participants | 8 Participants |
| Race (NIH/OMB) American Indian or Alaska Native | 0 Participants | 0 Participants | 0 Participants |
| Race (NIH/OMB) Asian | 0 Participants | 0 Participants | 0 Participants |
| Race (NIH/OMB) Black or African American | 1 Participants | 0 Participants | 1 Participants |
| Race (NIH/OMB) More than one race | 0 Participants | 0 Participants | 0 Participants |
| Race (NIH/OMB) Native Hawaiian or Other Pacific Islander | 0 Participants | 0 Participants | 0 Participants |
| Race (NIH/OMB) Unknown or Not Reported | 2 Participants | 0 Participants | 2 Participants |
| Race (NIH/OMB) White | 17 Participants | 5 Participants | 22 Participants |
| Region of Enrollment United States | 20 Participants | 5 Participants | 25 Participants |
| Sex: Female, Male Female | 2 Participants | 1 Participants | 3 Participants |
| Sex: Female, Male Male | 18 Participants | 4 Participants | 22 Participants |
Adverse events
| Event type | EG000 affected / at risk | EG001 affected / at risk |
|---|---|---|
| deaths Total, all-cause mortality | 4 / 20 | 0 / 5 |
| other Total, other adverse events | 20 / 20 | 5 / 5 |
| serious Total, serious adverse events | 20 / 20 | 2 / 5 |
Outcome results
Primary
Overall Response Rate (ORR) of Patients With Burkitt's and Burkitt-like Lymphoma/Leukemia Treated With Modified Magrath Regimen
Response Rate is defined as combined number of patients with Complete Remission (CR) Complete Remission undetermined (Cru) and Partial Remission (PR) for patients with Burkitt's and Burkitt-like Lymphoma/Leukemia. Response will be measured by CT scans following treatment completion and assessed using Response Criteria for Non-Hodgkin's Lymphoma where: CR=complete disappearance of all detectable clinical and radiographic evidence of disease and disappearance of all disease-related symptoms. CRu=same as above but allowing for 75% decrease in lymph node masses and indeterminate or normal bone marrow. PR=50% decrease in SPD of the six largest dominant nodes or nodal masses with no increase in size or other nodes, liver, spleen and no new sites of disease.
Time frame: After two cycles of treatment and at completion of treatment (4 cycles for high risk and 3 cycles for low risk) up to approximately 20 weeks.
Population: One patient was determined not to be evaluable for response as he did not complete 2 cycles that were required per protocol to be evaluable for this outcome measure
| Arm | Measure | Group | Value (NUMBER) |
|---|---|---|---|
| High Risk - Treated With Alternating R-CODOX-M/R-IVAC | Overall Response Rate (ORR) of Patients With Burkitt's and Burkitt-like Lymphoma/Leukemia Treated With Modified Magrath Regimen | ORR after two cycles of treatment | 100 percentage of patients |
| High Risk - Treated With Alternating R-CODOX-M/R-IVAC | Overall Response Rate (ORR) of Patients With Burkitt's and Burkitt-like Lymphoma/Leukemia Treated With Modified Magrath Regimen | ORR at completion of treatment | 100 percentage of patients |
| Low Risk - Treatment With 3 Cycles of R-CODOX-M | Overall Response Rate (ORR) of Patients With Burkitt's and Burkitt-like Lymphoma/Leukemia Treated With Modified Magrath Regimen | ORR after two cycles of treatment | 100 percentage of patients |
| Low Risk - Treatment With 3 Cycles of R-CODOX-M | Overall Response Rate (ORR) of Patients With Burkitt's and Burkitt-like Lymphoma/Leukemia Treated With Modified Magrath Regimen | ORR at completion of treatment | 100 percentage of patients |
Secondary
Overall Survival (OS) of Patients With Burkitt's and Burkitt-like Lymphoma/Leukemia Treated With Modified Magrath Regimen
Overall Survival (OS) of patients with Burkitt's and Burkitt-like Lymphoma/Leukemia treated with modified Magrath regimen. OS is defined from the first dose of study drug to the time of death for any reason.
Time frame: At 2 years from treatment initiation Median follow up 34 months (range 15-45)
Population: Evaluable patients for this outcome measure and were reported on together and in stratified group: high-risk and low-risk
| Arm | Measure | Value (NUMBER) |
|---|---|---|
| High Risk - Treated With Alternating R-CODOX-M/R-IVAC | Overall Survival (OS) of Patients With Burkitt's and Burkitt-like Lymphoma/Leukemia Treated With Modified Magrath Regimen | 81 percentage of patients alive |
| Low Risk - Treatment With 3 Cycles of R-CODOX-M | Overall Survival (OS) of Patients With Burkitt's and Burkitt-like Lymphoma/Leukemia Treated With Modified Magrath Regimen | 100 percentage of patients alive |
Secondary
Progression Free Survival (PFS) of Patients With Burkitt's and Burkitt-like Lymphoma/Leukemia Treated With Modified Magrath Regimen
Progression Free Survival (PFS) will be defined from the first dose of study drug to the first documentation of progressive disease or death for any reason. Patients that are lost to follow-up before progression will be censored at the point of last documentation of not experiencing the event.
Time frame: At 2 years from treatment initiation. Median follow up 34 months (range 15-45)
Population: Evaluable patients for this outcome measure and were reported on together and in stratified group: high-risk and low-risk
| Arm | Measure | Value (NUMBER) |
|---|---|---|
| High Risk - Treated With Alternating R-CODOX-M/R-IVAC | Progression Free Survival (PFS) of Patients With Burkitt's and Burkitt-like Lymphoma/Leukemia Treated With Modified Magrath Regimen | 76 percentage of patients progression free |
| Low Risk - Treatment With 3 Cycles of R-CODOX-M | Progression Free Survival (PFS) of Patients With Burkitt's and Burkitt-like Lymphoma/Leukemia Treated With Modified Magrath Regimen | 100 percentage of patients progression free |
Secondary
Safety of Patients With Burkitt's and Burkitt-like Lymphoma/Leukemia Treated With Modified Magrath Regimen (Addition of Rituximab, Subsitution of Adriamycin for Doxil and Using Lower Dose of Methotrexate)
Adverse events (AE) graded as either 3 or 4 and determined to be at least possibly related to study treatment will be collected in patients Burkitt's and Burkitt-like Lymphoma/Leukemia treated with modified Magrath regimen to assess the safety and toxicity profile of the addition of rituximab, subsitution of adriamycin for doxil and lower dose of methotrexate. AEs will be assessed as follows at the following time points: At the end of each cycle or monthly whichever is less frequent and 30 days post last dose of study treatment for a maximum of 3 cycles for regimen A and 4 cycles for regimen B and up to 12 months. In general AEs will be assessed according to the National Cancer Institute's Common Toxicity Criteria for adverse events version 3.0 (CTCAE v 3.0). In general adverse events (AEs) will be graded according to the following: Grade 1 Mild AE Grade 2 Moderate AE Grade 3 Severe AE Grade 4 Life-threatening or disabling AE Grade 5 Death related to AE
Time frame: After each cycle or monthly (whichever is less frequent), 30 days post last dose. Treatment duration was at a median of 13 weeks (range 11-20) for high-risk patients and 10 weeks (range 9-12) for low-risk patients.
Population: All patients that receive at least one dose of study drug are evaluable for this outcome measure
| Arm | Measure | Group | Value (NUMBER) |
|---|---|---|---|
| High Risk - Treated With Alternating R-CODOX-M/R-IVAC | Safety of Patients With Burkitt's and Burkitt-like Lymphoma/Leukemia Treated With Modified Magrath Regimen (Addition of Rituximab, Subsitution of Adriamycin for Doxil and Using Lower Dose of Methotrexate) | Elevated Transaminases : Grade 3 | 6 participants |
| High Risk - Treated With Alternating R-CODOX-M/R-IVAC | Safety of Patients With Burkitt's and Burkitt-like Lymphoma/Leukemia Treated With Modified Magrath Regimen (Addition of Rituximab, Subsitution of Adriamycin for Doxil and Using Lower Dose of Methotrexate) | Anemia : Grade 4 | 1 participants |
| High Risk - Treated With Alternating R-CODOX-M/R-IVAC | Safety of Patients With Burkitt's and Burkitt-like Lymphoma/Leukemia Treated With Modified Magrath Regimen (Addition of Rituximab, Subsitution of Adriamycin for Doxil and Using Lower Dose of Methotrexate) | Neutropenia : Grade 3 | 5 participants |
| High Risk - Treated With Alternating R-CODOX-M/R-IVAC | Safety of Patients With Burkitt's and Burkitt-like Lymphoma/Leukemia Treated With Modified Magrath Regimen (Addition of Rituximab, Subsitution of Adriamycin for Doxil and Using Lower Dose of Methotrexate) | Neutropenia : Grade 4 | 6 participants |
| High Risk - Treated With Alternating R-CODOX-M/R-IVAC | Safety of Patients With Burkitt's and Burkitt-like Lymphoma/Leukemia Treated With Modified Magrath Regimen (Addition of Rituximab, Subsitution of Adriamycin for Doxil and Using Lower Dose of Methotrexate) | Thrombocytopenia : Grade 3 | 1 participants |
| High Risk - Treated With Alternating R-CODOX-M/R-IVAC | Safety of Patients With Burkitt's and Burkitt-like Lymphoma/Leukemia Treated With Modified Magrath Regimen (Addition of Rituximab, Subsitution of Adriamycin for Doxil and Using Lower Dose of Methotrexate) | Thrombocytopenia : Grade 4 | 13 participants |
| High Risk - Treated With Alternating R-CODOX-M/R-IVAC | Safety of Patients With Burkitt's and Burkitt-like Lymphoma/Leukemia Treated With Modified Magrath Regimen (Addition of Rituximab, Subsitution of Adriamycin for Doxil and Using Lower Dose of Methotrexate) | Mucositis : Grade 3 | 7 participants |
| High Risk - Treated With Alternating R-CODOX-M/R-IVAC | Safety of Patients With Burkitt's and Burkitt-like Lymphoma/Leukemia Treated With Modified Magrath Regimen (Addition of Rituximab, Subsitution of Adriamycin for Doxil and Using Lower Dose of Methotrexate) | Mucositis : Grade 4 | 3 participants |
| High Risk - Treated With Alternating R-CODOX-M/R-IVAC | Safety of Patients With Burkitt's and Burkitt-like Lymphoma/Leukemia Treated With Modified Magrath Regimen (Addition of Rituximab, Subsitution of Adriamycin for Doxil and Using Lower Dose of Methotrexate) | Infection : Grade 3 | 8 participants |
| High Risk - Treated With Alternating R-CODOX-M/R-IVAC | Safety of Patients With Burkitt's and Burkitt-like Lymphoma/Leukemia Treated With Modified Magrath Regimen (Addition of Rituximab, Subsitution of Adriamycin for Doxil and Using Lower Dose of Methotrexate) | Infection : Grade 4 | 0 participants |
| High Risk - Treated With Alternating R-CODOX-M/R-IVAC | Safety of Patients With Burkitt's and Burkitt-like Lymphoma/Leukemia Treated With Modified Magrath Regimen (Addition of Rituximab, Subsitution of Adriamycin for Doxil and Using Lower Dose of Methotrexate) | Anemia : Grade 3 | 13 participants |
| High Risk - Treated With Alternating R-CODOX-M/R-IVAC | Safety of Patients With Burkitt's and Burkitt-like Lymphoma/Leukemia Treated With Modified Magrath Regimen (Addition of Rituximab, Subsitution of Adriamycin for Doxil and Using Lower Dose of Methotrexate) | Elevated Transaminases : Grade 4 | 0 participants |
| High Risk - Treated With Alternating R-CODOX-M/R-IVAC | Safety of Patients With Burkitt's and Burkitt-like Lymphoma/Leukemia Treated With Modified Magrath Regimen (Addition of Rituximab, Subsitution of Adriamycin for Doxil and Using Lower Dose of Methotrexate) | Fever (Neutropenic) : Grade 3 | 4 participants |
| High Risk - Treated With Alternating R-CODOX-M/R-IVAC | Safety of Patients With Burkitt's and Burkitt-like Lymphoma/Leukemia Treated With Modified Magrath Regimen (Addition of Rituximab, Subsitution of Adriamycin for Doxil and Using Lower Dose of Methotrexate) | Fever (Neutropenic) : Grade 4 | 0 participants |
| High Risk - Treated With Alternating R-CODOX-M/R-IVAC | Safety of Patients With Burkitt's and Burkitt-like Lymphoma/Leukemia Treated With Modified Magrath Regimen (Addition of Rituximab, Subsitution of Adriamycin for Doxil and Using Lower Dose of Methotrexate) | Low Phosphate : Grade 3 | 5 participants |
| High Risk - Treated With Alternating R-CODOX-M/R-IVAC | Safety of Patients With Burkitt's and Burkitt-like Lymphoma/Leukemia Treated With Modified Magrath Regimen (Addition of Rituximab, Subsitution of Adriamycin for Doxil and Using Lower Dose of Methotrexate) | Low Phosphate : Grade 4 | 0 participants |
| High Risk - Treated With Alternating R-CODOX-M/R-IVAC | Safety of Patients With Burkitt's and Burkitt-like Lymphoma/Leukemia Treated With Modified Magrath Regimen (Addition of Rituximab, Subsitution of Adriamycin for Doxil and Using Lower Dose of Methotrexate) | Sodium Abnormalities : Grade 3 | 4 participants |
| High Risk - Treated With Alternating R-CODOX-M/R-IVAC | Safety of Patients With Burkitt's and Burkitt-like Lymphoma/Leukemia Treated With Modified Magrath Regimen (Addition of Rituximab, Subsitution of Adriamycin for Doxil and Using Lower Dose of Methotrexate) | Sodium Abnormalities : Grade 4 | 0 participants |
| High Risk - Treated With Alternating R-CODOX-M/R-IVAC | Safety of Patients With Burkitt's and Burkitt-like Lymphoma/Leukemia Treated With Modified Magrath Regimen (Addition of Rituximab, Subsitution of Adriamycin for Doxil and Using Lower Dose of Methotrexate) | Hyperglycemia : Grade 3 | 1 participants |
| High Risk - Treated With Alternating R-CODOX-M/R-IVAC | Safety of Patients With Burkitt's and Burkitt-like Lymphoma/Leukemia Treated With Modified Magrath Regimen (Addition of Rituximab, Subsitution of Adriamycin for Doxil and Using Lower Dose of Methotrexate) | Hyperglycemia : Grade 4 | 5 participants |
| High Risk - Treated With Alternating R-CODOX-M/R-IVAC | Safety of Patients With Burkitt's and Burkitt-like Lymphoma/Leukemia Treated With Modified Magrath Regimen (Addition of Rituximab, Subsitution of Adriamycin for Doxil and Using Lower Dose of Methotrexate) | Hypoalbuminemia : Grade 3 | 4 participants |
| High Risk - Treated With Alternating R-CODOX-M/R-IVAC | Safety of Patients With Burkitt's and Burkitt-like Lymphoma/Leukemia Treated With Modified Magrath Regimen (Addition of Rituximab, Subsitution of Adriamycin for Doxil and Using Lower Dose of Methotrexate) | Hypoalbuminemia : Grade 4 | 0 participants |
| High Risk - Treated With Alternating R-CODOX-M/R-IVAC | Safety of Patients With Burkitt's and Burkitt-like Lymphoma/Leukemia Treated With Modified Magrath Regimen (Addition of Rituximab, Subsitution of Adriamycin for Doxil and Using Lower Dose of Methotrexate) | Hypokalemia : Grade 3 | 1 participants |
| High Risk - Treated With Alternating R-CODOX-M/R-IVAC | Safety of Patients With Burkitt's and Burkitt-like Lymphoma/Leukemia Treated With Modified Magrath Regimen (Addition of Rituximab, Subsitution of Adriamycin for Doxil and Using Lower Dose of Methotrexate) | Hypokalemia : Grade 4 | 0 participants |
| High Risk - Treated With Alternating R-CODOX-M/R-IVAC | Safety of Patients With Burkitt's and Burkitt-like Lymphoma/Leukemia Treated With Modified Magrath Regimen (Addition of Rituximab, Subsitution of Adriamycin for Doxil and Using Lower Dose of Methotrexate) | Cardiac : Grade 3 | 3 participants |
| High Risk - Treated With Alternating R-CODOX-M/R-IVAC | Safety of Patients With Burkitt's and Burkitt-like Lymphoma/Leukemia Treated With Modified Magrath Regimen (Addition of Rituximab, Subsitution of Adriamycin for Doxil and Using Lower Dose of Methotrexate) | Cardiac : Grade 4 | 0 participants |
| High Risk - Treated With Alternating R-CODOX-M/R-IVAC | Safety of Patients With Burkitt's and Burkitt-like Lymphoma/Leukemia Treated With Modified Magrath Regimen (Addition of Rituximab, Subsitution of Adriamycin for Doxil and Using Lower Dose of Methotrexate) | Diarrhea : Grade 3 | 2 participants |
| High Risk - Treated With Alternating R-CODOX-M/R-IVAC | Safety of Patients With Burkitt's and Burkitt-like Lymphoma/Leukemia Treated With Modified Magrath Regimen (Addition of Rituximab, Subsitution of Adriamycin for Doxil and Using Lower Dose of Methotrexate) | Diarrhea : Grade 4 | 0 participants |
| High Risk - Treated With Alternating R-CODOX-M/R-IVAC | Safety of Patients With Burkitt's and Burkitt-like Lymphoma/Leukemia Treated With Modified Magrath Regimen (Addition of Rituximab, Subsitution of Adriamycin for Doxil and Using Lower Dose of Methotrexate) | Elevated Creatinine : Grade 3 | 2 participants |
| High Risk - Treated With Alternating R-CODOX-M/R-IVAC | Safety of Patients With Burkitt's and Burkitt-like Lymphoma/Leukemia Treated With Modified Magrath Regimen (Addition of Rituximab, Subsitution of Adriamycin for Doxil and Using Lower Dose of Methotrexate) | Elevated Creatinine : Grade 4 | 0 participants |
| High Risk - Treated With Alternating R-CODOX-M/R-IVAC | Safety of Patients With Burkitt's and Burkitt-like Lymphoma/Leukemia Treated With Modified Magrath Regimen (Addition of Rituximab, Subsitution of Adriamycin for Doxil and Using Lower Dose of Methotrexate) | Nausea/Vomiting : Grade 3 | 1 participants |
| High Risk - Treated With Alternating R-CODOX-M/R-IVAC | Safety of Patients With Burkitt's and Burkitt-like Lymphoma/Leukemia Treated With Modified Magrath Regimen (Addition of Rituximab, Subsitution of Adriamycin for Doxil and Using Lower Dose of Methotrexate) | Nausea/Vomiting : Grade 4 | 0 participants |
| High Risk - Treated With Alternating R-CODOX-M/R-IVAC | Safety of Patients With Burkitt's and Burkitt-like Lymphoma/Leukemia Treated With Modified Magrath Regimen (Addition of Rituximab, Subsitution of Adriamycin for Doxil and Using Lower Dose of Methotrexate) | Low Blood Pressure : Grade 3 | 1 participants |
| High Risk - Treated With Alternating R-CODOX-M/R-IVAC | Safety of Patients With Burkitt's and Burkitt-like Lymphoma/Leukemia Treated With Modified Magrath Regimen (Addition of Rituximab, Subsitution of Adriamycin for Doxil and Using Lower Dose of Methotrexate) | Low Blood Pressure : Grade 4 | 0 participants |
| High Risk - Treated With Alternating R-CODOX-M/R-IVAC | Safety of Patients With Burkitt's and Burkitt-like Lymphoma/Leukemia Treated With Modified Magrath Regimen (Addition of Rituximab, Subsitution of Adriamycin for Doxil and Using Lower Dose of Methotrexate) | Rash : Grade 3 | 1 participants |
| High Risk - Treated With Alternating R-CODOX-M/R-IVAC | Safety of Patients With Burkitt's and Burkitt-like Lymphoma/Leukemia Treated With Modified Magrath Regimen (Addition of Rituximab, Subsitution of Adriamycin for Doxil and Using Lower Dose of Methotrexate) | Rash : Grade 4 | 0 participants |
| High Risk - Treated With Alternating R-CODOX-M/R-IVAC | Safety of Patients With Burkitt's and Burkitt-like Lymphoma/Leukemia Treated With Modified Magrath Regimen (Addition of Rituximab, Subsitution of Adriamycin for Doxil and Using Lower Dose of Methotrexate) | Edema : Grade 3 | 1 participants |
| High Risk - Treated With Alternating R-CODOX-M/R-IVAC | Safety of Patients With Burkitt's and Burkitt-like Lymphoma/Leukemia Treated With Modified Magrath Regimen (Addition of Rituximab, Subsitution of Adriamycin for Doxil and Using Lower Dose of Methotrexate) | Edema : Grade 4 | 0 participants |
| High Risk - Treated With Alternating R-CODOX-M/R-IVAC | Safety of Patients With Burkitt's and Burkitt-like Lymphoma/Leukemia Treated With Modified Magrath Regimen (Addition of Rituximab, Subsitution of Adriamycin for Doxil and Using Lower Dose of Methotrexate) | Low Magnesium : Grade 3 | 1 participants |
| High Risk - Treated With Alternating R-CODOX-M/R-IVAC | Safety of Patients With Burkitt's and Burkitt-like Lymphoma/Leukemia Treated With Modified Magrath Regimen (Addition of Rituximab, Subsitution of Adriamycin for Doxil and Using Lower Dose of Methotrexate) | Low Magnesium : Grade 4 | 0 participants |
| Low Risk - Treatment With 3 Cycles of R-CODOX-M | Safety of Patients With Burkitt's and Burkitt-like Lymphoma/Leukemia Treated With Modified Magrath Regimen (Addition of Rituximab, Subsitution of Adriamycin for Doxil and Using Lower Dose of Methotrexate) | Edema : Grade 4 | 0 participants |
| Low Risk - Treatment With 3 Cycles of R-CODOX-M | Safety of Patients With Burkitt's and Burkitt-like Lymphoma/Leukemia Treated With Modified Magrath Regimen (Addition of Rituximab, Subsitution of Adriamycin for Doxil and Using Lower Dose of Methotrexate) | Anemia : Grade 3 | 3 participants |
| Low Risk - Treatment With 3 Cycles of R-CODOX-M | Safety of Patients With Burkitt's and Burkitt-like Lymphoma/Leukemia Treated With Modified Magrath Regimen (Addition of Rituximab, Subsitution of Adriamycin for Doxil and Using Lower Dose of Methotrexate) | Hypoalbuminemia : Grade 3 | 0 participants |
| Low Risk - Treatment With 3 Cycles of R-CODOX-M | Safety of Patients With Burkitt's and Burkitt-like Lymphoma/Leukemia Treated With Modified Magrath Regimen (Addition of Rituximab, Subsitution of Adriamycin for Doxil and Using Lower Dose of Methotrexate) | Anemia : Grade 4 | 0 participants |
| Low Risk - Treatment With 3 Cycles of R-CODOX-M | Safety of Patients With Burkitt's and Burkitt-like Lymphoma/Leukemia Treated With Modified Magrath Regimen (Addition of Rituximab, Subsitution of Adriamycin for Doxil and Using Lower Dose of Methotrexate) | Nausea/Vomiting : Grade 3 | 0 participants |
| Low Risk - Treatment With 3 Cycles of R-CODOX-M | Safety of Patients With Burkitt's and Burkitt-like Lymphoma/Leukemia Treated With Modified Magrath Regimen (Addition of Rituximab, Subsitution of Adriamycin for Doxil and Using Lower Dose of Methotrexate) | Neutropenia : Grade 3 | 2 participants |
| Low Risk - Treatment With 3 Cycles of R-CODOX-M | Safety of Patients With Burkitt's and Burkitt-like Lymphoma/Leukemia Treated With Modified Magrath Regimen (Addition of Rituximab, Subsitution of Adriamycin for Doxil and Using Lower Dose of Methotrexate) | Hypoalbuminemia : Grade 4 | 0 participants |
| Low Risk - Treatment With 3 Cycles of R-CODOX-M | Safety of Patients With Burkitt's and Burkitt-like Lymphoma/Leukemia Treated With Modified Magrath Regimen (Addition of Rituximab, Subsitution of Adriamycin for Doxil and Using Lower Dose of Methotrexate) | Neutropenia : Grade 4 | 2 participants |
| Low Risk - Treatment With 3 Cycles of R-CODOX-M | Safety of Patients With Burkitt's and Burkitt-like Lymphoma/Leukemia Treated With Modified Magrath Regimen (Addition of Rituximab, Subsitution of Adriamycin for Doxil and Using Lower Dose of Methotrexate) | Rash : Grade 4 | 0 participants |
| Low Risk - Treatment With 3 Cycles of R-CODOX-M | Safety of Patients With Burkitt's and Burkitt-like Lymphoma/Leukemia Treated With Modified Magrath Regimen (Addition of Rituximab, Subsitution of Adriamycin for Doxil and Using Lower Dose of Methotrexate) | Thrombocytopenia : Grade 3 | 1 participants |
| Low Risk - Treatment With 3 Cycles of R-CODOX-M | Safety of Patients With Burkitt's and Burkitt-like Lymphoma/Leukemia Treated With Modified Magrath Regimen (Addition of Rituximab, Subsitution of Adriamycin for Doxil and Using Lower Dose of Methotrexate) | Hypokalemia : Grade 3 | 2 participants |
| Low Risk - Treatment With 3 Cycles of R-CODOX-M | Safety of Patients With Burkitt's and Burkitt-like Lymphoma/Leukemia Treated With Modified Magrath Regimen (Addition of Rituximab, Subsitution of Adriamycin for Doxil and Using Lower Dose of Methotrexate) | Thrombocytopenia : Grade 4 | 2 participants |
| Low Risk - Treatment With 3 Cycles of R-CODOX-M | Safety of Patients With Burkitt's and Burkitt-like Lymphoma/Leukemia Treated With Modified Magrath Regimen (Addition of Rituximab, Subsitution of Adriamycin for Doxil and Using Lower Dose of Methotrexate) | Nausea/Vomiting : Grade 4 | 0 participants |
| Low Risk - Treatment With 3 Cycles of R-CODOX-M | Safety of Patients With Burkitt's and Burkitt-like Lymphoma/Leukemia Treated With Modified Magrath Regimen (Addition of Rituximab, Subsitution of Adriamycin for Doxil and Using Lower Dose of Methotrexate) | Mucositis : Grade 3 | 2 participants |
| Low Risk - Treatment With 3 Cycles of R-CODOX-M | Safety of Patients With Burkitt's and Burkitt-like Lymphoma/Leukemia Treated With Modified Magrath Regimen (Addition of Rituximab, Subsitution of Adriamycin for Doxil and Using Lower Dose of Methotrexate) | Hypokalemia : Grade 4 | 0 participants |
| Low Risk - Treatment With 3 Cycles of R-CODOX-M | Safety of Patients With Burkitt's and Burkitt-like Lymphoma/Leukemia Treated With Modified Magrath Regimen (Addition of Rituximab, Subsitution of Adriamycin for Doxil and Using Lower Dose of Methotrexate) | Mucositis : Grade 4 | 0 participants |
| Low Risk - Treatment With 3 Cycles of R-CODOX-M | Safety of Patients With Burkitt's and Burkitt-like Lymphoma/Leukemia Treated With Modified Magrath Regimen (Addition of Rituximab, Subsitution of Adriamycin for Doxil and Using Lower Dose of Methotrexate) | Low Magnesium : Grade 4 | 0 participants |
| Low Risk - Treatment With 3 Cycles of R-CODOX-M | Safety of Patients With Burkitt's and Burkitt-like Lymphoma/Leukemia Treated With Modified Magrath Regimen (Addition of Rituximab, Subsitution of Adriamycin for Doxil and Using Lower Dose of Methotrexate) | Infection : Grade 3 | 1 participants |
| Low Risk - Treatment With 3 Cycles of R-CODOX-M | Safety of Patients With Burkitt's and Burkitt-like Lymphoma/Leukemia Treated With Modified Magrath Regimen (Addition of Rituximab, Subsitution of Adriamycin for Doxil and Using Lower Dose of Methotrexate) | Cardiac : Grade 3 | 0 participants |
| Low Risk - Treatment With 3 Cycles of R-CODOX-M | Safety of Patients With Burkitt's and Burkitt-like Lymphoma/Leukemia Treated With Modified Magrath Regimen (Addition of Rituximab, Subsitution of Adriamycin for Doxil and Using Lower Dose of Methotrexate) | Infection : Grade 4 | 0 participants |
| Low Risk - Treatment With 3 Cycles of R-CODOX-M | Safety of Patients With Burkitt's and Burkitt-like Lymphoma/Leukemia Treated With Modified Magrath Regimen (Addition of Rituximab, Subsitution of Adriamycin for Doxil and Using Lower Dose of Methotrexate) | Low Blood Pressure : Grade 3 | 0 participants |
| Low Risk - Treatment With 3 Cycles of R-CODOX-M | Safety of Patients With Burkitt's and Burkitt-like Lymphoma/Leukemia Treated With Modified Magrath Regimen (Addition of Rituximab, Subsitution of Adriamycin for Doxil and Using Lower Dose of Methotrexate) | Elevated Transaminases : Grade 3 | 2 participants |
| Low Risk - Treatment With 3 Cycles of R-CODOX-M | Safety of Patients With Burkitt's and Burkitt-like Lymphoma/Leukemia Treated With Modified Magrath Regimen (Addition of Rituximab, Subsitution of Adriamycin for Doxil and Using Lower Dose of Methotrexate) | Cardiac : Grade 4 | 0 participants |
| Low Risk - Treatment With 3 Cycles of R-CODOX-M | Safety of Patients With Burkitt's and Burkitt-like Lymphoma/Leukemia Treated With Modified Magrath Regimen (Addition of Rituximab, Subsitution of Adriamycin for Doxil and Using Lower Dose of Methotrexate) | Elevated Transaminases : Grade 4 | 0 participants |
| Low Risk - Treatment With 3 Cycles of R-CODOX-M | Safety of Patients With Burkitt's and Burkitt-like Lymphoma/Leukemia Treated With Modified Magrath Regimen (Addition of Rituximab, Subsitution of Adriamycin for Doxil and Using Lower Dose of Methotrexate) | Edema : Grade 3 | 0 participants |
| Low Risk - Treatment With 3 Cycles of R-CODOX-M | Safety of Patients With Burkitt's and Burkitt-like Lymphoma/Leukemia Treated With Modified Magrath Regimen (Addition of Rituximab, Subsitution of Adriamycin for Doxil and Using Lower Dose of Methotrexate) | Fever (Neutropenic) : Grade 3 | 3 participants |
| Low Risk - Treatment With 3 Cycles of R-CODOX-M | Safety of Patients With Burkitt's and Burkitt-like Lymphoma/Leukemia Treated With Modified Magrath Regimen (Addition of Rituximab, Subsitution of Adriamycin for Doxil and Using Lower Dose of Methotrexate) | Diarrhea : Grade 3 | 0 participants |
| Low Risk - Treatment With 3 Cycles of R-CODOX-M | Safety of Patients With Burkitt's and Burkitt-like Lymphoma/Leukemia Treated With Modified Magrath Regimen (Addition of Rituximab, Subsitution of Adriamycin for Doxil and Using Lower Dose of Methotrexate) | Fever (Neutropenic) : Grade 4 | 0 participants |
| Low Risk - Treatment With 3 Cycles of R-CODOX-M | Safety of Patients With Burkitt's and Burkitt-like Lymphoma/Leukemia Treated With Modified Magrath Regimen (Addition of Rituximab, Subsitution of Adriamycin for Doxil and Using Lower Dose of Methotrexate) | Low Blood Pressure : Grade 4 | 0 participants |
| Low Risk - Treatment With 3 Cycles of R-CODOX-M | Safety of Patients With Burkitt's and Burkitt-like Lymphoma/Leukemia Treated With Modified Magrath Regimen (Addition of Rituximab, Subsitution of Adriamycin for Doxil and Using Lower Dose of Methotrexate) | Low Phosphate : Grade 3 | 1 participants |
| Low Risk - Treatment With 3 Cycles of R-CODOX-M | Safety of Patients With Burkitt's and Burkitt-like Lymphoma/Leukemia Treated With Modified Magrath Regimen (Addition of Rituximab, Subsitution of Adriamycin for Doxil and Using Lower Dose of Methotrexate) | Diarrhea : Grade 4 | 0 participants |
| Low Risk - Treatment With 3 Cycles of R-CODOX-M | Safety of Patients With Burkitt's and Burkitt-like Lymphoma/Leukemia Treated With Modified Magrath Regimen (Addition of Rituximab, Subsitution of Adriamycin for Doxil and Using Lower Dose of Methotrexate) | Low Phosphate : Grade 4 | 0 participants |
| Low Risk - Treatment With 3 Cycles of R-CODOX-M | Safety of Patients With Burkitt's and Burkitt-like Lymphoma/Leukemia Treated With Modified Magrath Regimen (Addition of Rituximab, Subsitution of Adriamycin for Doxil and Using Lower Dose of Methotrexate) | Low Magnesium : Grade 3 | 0 participants |
| Low Risk - Treatment With 3 Cycles of R-CODOX-M | Safety of Patients With Burkitt's and Burkitt-like Lymphoma/Leukemia Treated With Modified Magrath Regimen (Addition of Rituximab, Subsitution of Adriamycin for Doxil and Using Lower Dose of Methotrexate) | Sodium Abnormalities : Grade 3 | 2 participants |
| Low Risk - Treatment With 3 Cycles of R-CODOX-M | Safety of Patients With Burkitt's and Burkitt-like Lymphoma/Leukemia Treated With Modified Magrath Regimen (Addition of Rituximab, Subsitution of Adriamycin for Doxil and Using Lower Dose of Methotrexate) | Elevated Creatinine : Grade 3 | 0 participants |
| Low Risk - Treatment With 3 Cycles of R-CODOX-M | Safety of Patients With Burkitt's and Burkitt-like Lymphoma/Leukemia Treated With Modified Magrath Regimen (Addition of Rituximab, Subsitution of Adriamycin for Doxil and Using Lower Dose of Methotrexate) | Sodium Abnormalities : Grade 4 | 0 participants |
| Low Risk - Treatment With 3 Cycles of R-CODOX-M | Safety of Patients With Burkitt's and Burkitt-like Lymphoma/Leukemia Treated With Modified Magrath Regimen (Addition of Rituximab, Subsitution of Adriamycin for Doxil and Using Lower Dose of Methotrexate) | Rash : Grade 3 | 0 participants |
| Low Risk - Treatment With 3 Cycles of R-CODOX-M | Safety of Patients With Burkitt's and Burkitt-like Lymphoma/Leukemia Treated With Modified Magrath Regimen (Addition of Rituximab, Subsitution of Adriamycin for Doxil and Using Lower Dose of Methotrexate) | Hyperglycemia : Grade 3 | 3 participants |
| Low Risk - Treatment With 3 Cycles of R-CODOX-M | Safety of Patients With Burkitt's and Burkitt-like Lymphoma/Leukemia Treated With Modified Magrath Regimen (Addition of Rituximab, Subsitution of Adriamycin for Doxil and Using Lower Dose of Methotrexate) | Elevated Creatinine : Grade 4 | 0 participants |
| Low Risk - Treatment With 3 Cycles of R-CODOX-M | Safety of Patients With Burkitt's and Burkitt-like Lymphoma/Leukemia Treated With Modified Magrath Regimen (Addition of Rituximab, Subsitution of Adriamycin for Doxil and Using Lower Dose of Methotrexate) | Hyperglycemia : Grade 4 | 0 participants |